Skip to main content
Erschienen in: memo - Magazine of European Medical Oncology 3/2012

01.09.2012 | short review

Brief update on recent developments in CML

verfasst von: Stefan Schmidt, MD

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 3/2012

Einloggen, um Zugang zu erhalten

Abstract

The approval of dasatinib and nilotinib for first line treatment of chronic myeloid leukemia (CML) in chronic phase (CP) opened new therapeutic options. However, their role in this setting is yet undefined and additionally recent landmark studies have laid ground to re-discuss which response milestones are relevant for treatment guidance. Thus, updated data on these issues at last year’s ASH meeting were expected to potentially hint to what the new management standards might be. This short review briefly summarizes the respective evidence for (a) the outcome predictive value of early and deep molecular responses, (b) the superiority of second generation tyrosine kinase inhibitors (TKIs) to imatinib with regard to cytogenetic and molecular response rates, (c) the (yet) lacking proof of a survival benefit of second generation TKIs and (d) the role of new TKIs and alternative treatment strategies. Chronic myeloid leukemia (CML) has become a paradigm for targeted medicine; however, despite their impressive therapeutic success, TKIs offer disease control rather than disease eradication. The development of second generation TKIs broadened therapeutic options and consecutively disease management recommendations focused on response monitoring to guide change of treatment upon patient’s individual failure to respond. This short review will focus on ASH updates on second generation TKIs in first line treatment, potential future definitions of response milestones, and briefly on new TKIs and alternative TKI treatment concepts.
Literatur
1.
Zurück zum Zitat Kantarjian HM, Shah NP, Cortes JE, Baccarani M, Agarwal MB, Undurraga MS, et al. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood. 2012 Feb 2;119(5):1123–9.PubMedCrossRef Kantarjian HM, Shah NP, Cortes JE, Baccarani M, Agarwal MB, Undurraga MS, et al. Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood. 2012 Feb 2;119(5):1123–9.PubMedCrossRef
2.
Zurück zum Zitat Hochhaus A, Saglio G, Chuah C, Pavlovsky C, Garelick MBB, Lambert A, et al. Dasatinib and imatinib-induced reductions in BCR-ABL transcript levels below 10 % at 3 months are associated with improved responses in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): analysis of molecular response kinetics in the DASISION trial. ASH Annual Meeting Abstracts. 2011 Nov 18;118(21):2767. Hochhaus A, Saglio G, Chuah C, Pavlovsky C, Garelick MBB, Lambert A, et al. Dasatinib and imatinib-induced reductions in BCR-ABL transcript levels below 10 % at 3 months are associated with improved responses in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP): analysis of molecular response kinetics in the DASISION trial. ASH Annual Meeting Abstracts. 2011 Nov 18;118(21):2767.
3.
Zurück zum Zitat Pemmaraju N, Kantarjian HM, Luthra R, O’Brien S, Jabbour E, Quintas-Cardama A, et al. Results of a phase II trial of dasatinib as frontline therapy for chronic myeloid leukemia (CML) in chronic phase (CP). ASH Annual Meeting Abstracts. 2011 Nov 18;118(21):1700. Pemmaraju N, Kantarjian HM, Luthra R, O’Brien S, Jabbour E, Quintas-Cardama A, et al. Results of a phase II trial of dasatinib as frontline therapy for chronic myeloid leukemia (CML) in chronic phase (CP). ASH Annual Meeting Abstracts. 2011 Nov 18;118(21):1700.
4.
Zurück zum Zitat Quintas-Cardama A, Kantarjian HM, Luthra R, O’Brien S, Jabbour E, Borthakur G, et al. Efficacy of frontline nilotinib therapy in patients (Pts) with newly diagnosed Philadelphia chromosome (Ph)-positive chronic myeloid leukemia in early chronic phase (CML-CP). ASH Annual Meeting Abstracts. 2011 Nov 18;118(21):454. Quintas-Cardama A, Kantarjian HM, Luthra R, O’Brien S, Jabbour E, Borthakur G, et al. Efficacy of frontline nilotinib therapy in patients (Pts) with newly diagnosed Philadelphia chromosome (Ph)-positive chronic myeloid leukemia in early chronic phase (CML-CP). ASH Annual Meeting Abstracts. 2011 Nov 18;118(21):454.
5.
Zurück zum Zitat Le Coutre PD, Giles FJ, Pinilla-Ibarz J, Larson RA, Gattermann N, Ottmann OG, et al. Nilotinib in imatinib-resistant or -intolerant patients (Pts) with chronic myeloid leukemia in chronic phase (CML-CP): 48-month follow-up results of a phase 2 study. ASH Annual Meeting Abstracts. 2011 Nov 18;118(21):3770. Le Coutre PD, Giles FJ, Pinilla-Ibarz J, Larson RA, Gattermann N, Ottmann OG, et al. Nilotinib in imatinib-resistant or -intolerant patients (Pts) with chronic myeloid leukemia in chronic phase (CML-CP): 48-month follow-up results of a phase 2 study. ASH Annual Meeting Abstracts. 2011 Nov 18;118(21):3770.
6.
Zurück zum Zitat Kantarjian H, O’Brien S, Jabbour E, Shan J, Ravandi F, Kadia T, et al. Impact of treatment end point definitions on perceived differences in long-term outcome with tyrosine kinase inhibitor therapy in chronic myeloid leukemia. J Clin Oncol. 2011 Aug 10;29(23):3173–8.PubMedCrossRef Kantarjian H, O’Brien S, Jabbour E, Shan J, Ravandi F, Kadia T, et al. Impact of treatment end point definitions on perceived differences in long-term outcome with tyrosine kinase inhibitor therapy in chronic myeloid leukemia. J Clin Oncol. 2011 Aug 10;29(23):3173–8.PubMedCrossRef
7.
Zurück zum Zitat Yeung DT, Osborn M, White DL, Branford S, Kornhauser M, Slader C, et al. Upfront imatinib therapy in CML patients with rapid switching to nilotinib for failure to achieve molecular targets or intolerance achieves high overall rates of molecular response and a low risk of progression—an update of the TIDEL-II trial. ASH Annual Meeting Abstracts. 2011 Nov 18;118(21):451. Yeung DT, Osborn M, White DL, Branford S, Kornhauser M, Slader C, et al. Upfront imatinib therapy in CML patients with rapid switching to nilotinib for failure to achieve molecular targets or intolerance achieves high overall rates of molecular response and a low risk of progression—an update of the TIDEL-II trial. ASH Annual Meeting Abstracts. 2011 Nov 18;118(21):451.
8.
Zurück zum Zitat Nicolini FE, Hayette S, Labussiere H, Etienne M, Fort MP, Gadolet E, et al. The month three major molecular response in chronic phase chronic myeloid leukemia on imatinib400, nilotinib and dasatinib is a major prognostic factor for failure-free and progression-free survival. ASH Annual Meeting Abstracts. 2011 Nov 18;118(21):1684. Nicolini FE, Hayette S, Labussiere H, Etienne M, Fort MP, Gadolet E, et al. The month three major molecular response in chronic phase chronic myeloid leukemia on imatinib400, nilotinib and dasatinib is a major prognostic factor for failure-free and progression-free survival. ASH Annual Meeting Abstracts. 2011 Nov 18;118(21):1684.
9.
Zurück zum Zitat Hanfstein B, Muller MC, Erben P, Lauseker M, Saussele S, Proetel U, et al. Molecular and cytogenetic response after 3 months of imatinib treatment is predictive for the risk of disease progression and death in newly diagnosed chronic myeloid leukemia patients—a follow-up analysis of the German CML study IV. ASH Annual Meeting Abstracts. 2011 Nov 18;118(21):783. Hanfstein B, Muller MC, Erben P, Lauseker M, Saussele S, Proetel U, et al. Molecular and cytogenetic response after 3 months of imatinib treatment is predictive for the risk of disease progression and death in newly diagnosed chronic myeloid leukemia patients—a follow-up analysis of the German CML study IV. ASH Annual Meeting Abstracts. 2011 Nov 18;118(21):783.
10.
Zurück zum Zitat Muller MC, Hanfstein B, Lauseker M, Erben P, Proetel U, Schnittger S, et al. Time-related interpretation of molecular response levels according to long term overall and progression-free survival of CML patients on first-line imatinib treatment. ASH Annual Meeting Abstracts. 2011 Nov 18;118(21):1681. Muller MC, Hanfstein B, Lauseker M, Erben P, Proetel U, Schnittger S, et al. Time-related interpretation of molecular response levels according to long term overall and progression-free survival of CML patients on first-line imatinib treatment. ASH Annual Meeting Abstracts. 2011 Nov 18;118(21):1681.
11.
Zurück zum Zitat Milojkovic D, Ibrahim AR, Foroni L, Lucas C, Gerrard G, Wang L, et al. Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with imatinib. ASH Annual Meeting Abstracts. 2011 Nov 18;118(21):1680. Milojkovic D, Ibrahim AR, Foroni L, Lucas C, Gerrard G, Wang L, et al. Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with imatinib. ASH Annual Meeting Abstracts. 2011 Nov 18;118(21):1680.
12.
Zurück zum Zitat Marin D, Ibrahim AR, Lucas C, Gerrard G, Wang L, Szydlo RM, et al. Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Clin Oncol. 2012 Jan 20;30(3):232–8.PubMedCrossRef Marin D, Ibrahim AR, Lucas C, Gerrard G, Wang L, Szydlo RM, et al. Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors. J Clin Oncol. 2012 Jan 20;30(3):232–8.PubMedCrossRef
13.
Zurück zum Zitat White DL, Saunders VA, Dang P, Engler J, Venables A, Zrim S, et al. Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity. Blood. 2007 Dec 1;110(12):4064–72.PubMedCrossRef White DL, Saunders VA, Dang P, Engler J, Venables A, Zrim S, et al. Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity. Blood. 2007 Dec 1;110(12):4064–72.PubMedCrossRef
14.
Zurück zum Zitat White DL, Hughes TP. Classification of patients with chronic myeloid leukemia on basis of BCR-ABL transcript level at 3 months fails to identify patients with low organic cation transporter-1 activity destined to have poor imatinib response. J Clin Oncol. 2012 Mar 5. White DL, Hughes TP. Classification of patients with chronic myeloid leukemia on basis of BCR-ABL transcript level at 3 months fails to identify patients with low organic cation transporter-1 activity destined to have poor imatinib response. J Clin Oncol. 2012 Mar 5.
15.
Zurück zum Zitat Hanfstein B, Muller MC, Hehlmann R, Erben P, Lauseker M, Fabarius A, et al. Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia. 2012 Mar 26. Hanfstein B, Muller MC, Hehlmann R, Erben P, Lauseker M, Fabarius A, et al. Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia. 2012 Mar 26.
16.
Zurück zum Zitat Cortes JE, Maru A, Souza CAAD, Guilhot F, Duvillie L, Powell C, et al. Bosutinib versus imatinib in newly diagnosed chronic phase chronic myeloid leukemia—BELA trial: 24-month follow-up. ASH Annual Meeting Abstracts. 2011 Nov 18;118(21):455. Cortes JE, Maru A, Souza CAAD, Guilhot F, Duvillie L, Powell C, et al. Bosutinib versus imatinib in newly diagnosed chronic phase chronic myeloid leukemia—BELA trial: 24-month follow-up. ASH Annual Meeting Abstracts. 2011 Nov 18;118(21):455.
17.
Zurück zum Zitat Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre PD, Chuah C, Nicolini FE, et al. Initial findings from the PACE trial: a pivotal phase 2 study of ponatinib in patients with CML and Ph + all resistant or intolerant to dasatinib or nilotinib, or with the T315I mutation. ASH Annual Meeting Abstracts. 2011 Nov 18;118(21):109. Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre PD, Chuah C, Nicolini FE, et al. Initial findings from the PACE trial: a pivotal phase 2 study of ponatinib in patients with CML and Ph + all resistant or intolerant to dasatinib or nilotinib, or with the T315I mutation. ASH Annual Meeting Abstracts. 2011 Nov 18;118(21):109.
18.
Zurück zum Zitat Castagnetti F, Rosti G, Breccia M, Gozzini A, Stagno F, Cambrin GR, et al. Alternating nilotinib 400 mg twice daily and imatinib 400 mg once daily as frontline treatment of Ph + chronic myeloid leukemia. A phase 2 multicentric study of the GIMEMA CML working party. ASH Annual Meeting Abstracts. 2011 Nov 18;118(21):453. Castagnetti F, Rosti G, Breccia M, Gozzini A, Stagno F, Cambrin GR, et al. Alternating nilotinib 400 mg twice daily and imatinib 400 mg once daily as frontline treatment of Ph + chronic myeloid leukemia. A phase 2 multicentric study of the GIMEMA CML working party. ASH Annual Meeting Abstracts. 2011 Nov 18;118(21):453.
19.
Zurück zum Zitat Hughes TP, Hochhaus A, Saglio G, Kim DW, Jootar S, Coutre PD, et al. ENESTnd update: continued superiority of nilotinib versus imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP). ASH Annual Meeting Abstracts. 2010 Nov 19;116(21):207. Hughes TP, Hochhaus A, Saglio G, Kim DW, Jootar S, Coutre PD, et al. ENESTnd update: continued superiority of nilotinib versus imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP). ASH Annual Meeting Abstracts. 2010 Nov 19;116(21):207.
20.
Zurück zum Zitat Mahon FX, Rea D, Guilhot J, Guilhot F, Huguet F, Nicolini FE, et al. Discontinuation of imatinib in patients with chronic myeloid leukemia who have maintained complete molecular response: update results of the STIM study. ASH Annual Meeting Abstracts. 2011 Nov 18;118(21):603. Mahon FX, Rea D, Guilhot J, Guilhot F, Huguet F, Nicolini FE, et al. Discontinuation of imatinib in patients with chronic myeloid leukemia who have maintained complete molecular response: update results of the STIM study. ASH Annual Meeting Abstracts. 2011 Nov 18;118(21):603.
21.
Zurück zum Zitat Milojkovic D, Gerrard G, Paliompeis C, Bua M, Reid A, Alikian M, et al. The natural history of RTQ-PCR levels after the achievement of complete molecular remission (CMR): implications for ‘stopping’ studies. ASH Annual Meeting Abstracts. 2011 Nov 18;118(21):605. Milojkovic D, Gerrard G, Paliompeis C, Bua M, Reid A, Alikian M, et al. The natural history of RTQ-PCR levels after the achievement of complete molecular remission (CMR): implications for ‘stopping’ studies. ASH Annual Meeting Abstracts. 2011 Nov 18;118(21):605.
Metadaten
Titel
Brief update on recent developments in CML
verfasst von
Stefan Schmidt, MD
Publikationsdatum
01.09.2012
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 3/2012
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-012-0029-9

Weitere Artikel der Ausgabe 3/2012

memo - Magazine of European Medical Oncology 3/2012 Zur Ausgabe